Cebon J - Search Results

1

Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.

Andrews MC, Turner N, Boyd J, Roberts AW, Grigg AP, Behren A, Cebon J. Andrews MC, et al. Among authors: cebon j. Clin Cancer Res. 2015 Dec 1;21(23):5222-34. doi: 10.1158/1078-0432.CCR-15-0393. Epub 2015 Jul 22. Clin Cancer Res. 2015. PMID: 26202951

2

Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies.

Sheridan WP, Begley CG, To LB, Grigg A, Szer J, Maher D, Green MD, Rowlings PA, McGrath KM, Cebon J, et al. Sheridan WP, et al. Among authors: cebon j. Bone Marrow Transplant. 1994 Jul;14(1):105-11. Bone Marrow Transplant. 1994. PMID: 7524904 Clinical Trial.

3

Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation.

O'Malley CJ, Rasko JE, Basser RL, McGrath KM, Cebon J, Grigg AP, Hopkins W, Cohen B, O'Byrne J, Green MD, Fox RM, Berndt MC, Begley CG. O'Malley CJ, et al. Among authors: cebon j. Blood. 1996 Nov 1;88(9):3288-98. Blood. 1996. PMID: 8896392 Free article. Clinical Trial.

4

Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.

Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Grigg AP, Zalcberg J, Cohen B, O'Byrne J, Menchaca DM, Fox RM, Begley CG. Basser RL, et al. Among authors: cebon j. Blood. 1997 May 1;89(9):3118-28. Blood. 1997. PMID: 9129014 Free article. Clinical Trial.

5

Viability and quantification of progenitor cells in venesected blood from patients receiving escalated-dose epirubicin and cyclophosphamide with G-CSF for lymphoma: potential role in further increasing dose-intensity.

O'Flaherty E, Cebon J, Grigg AP. O'Flaherty E, et al. Among authors: cebon j. Leuk Lymphoma. 1997 Oct;27(3-4):343-9. doi: 10.3109/10428199709059689. Leuk Lymphoma. 1997. PMID: 9402332

6

Cardiac metastases from malignant melanoma.

Gibbs P, Cebon JS, Calafiore P, Robinson WA. Gibbs P, et al. Among authors: cebon js. Cancer. 1999 Jan 1;85(1):78-84. Cancer. 1999. PMID: 9921977 Review.

7

A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours.

Mitchell PL, Basser R, Chipman M, Grigg A, Cebon J, Davis ID, Zalcberg J, Ng S, Appia F, Green M. Mitchell PL, et al. Among authors: cebon j. Ann Oncol. 2003 May;14(5):788-94. doi: 10.1093/annonc/mdg202. Ann Oncol. 2003. PMID: 12702535 Free article. Clinical Trial.

8

A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer.

Gunawardana DH, Basser RL, Davis ID, Cebon J, Mitchell P, Underhill C, Kilpatrick TJ, Reardon K, Green MD, Bardy P, Amor P, Crump D, Ng S, Nation RL, Begley CG. Gunawardana DH, et al. Among authors: cebon j. Clin Cancer Res. 2003 Jun;9(6):2056-65. Clin Cancer Res. 2003. PMID: 12796368 Clinical Trial.

9

A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.

Mitchell PL, Basser R, Chipman M, Grigg A, Mansfield R, Cebon J, Davis ID, Appia F, Green M. Mitchell PL, et al. Among authors: cebon j. Ann Oncol. 2004 Apr;15(4):585-9. doi: 10.1093/annonc/mdh144. Ann Oncol. 2004. PMID: 15033663 Free article. Clinical Trial.

10

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.

Maraskovsky E, Sjölander S, Drane DP, Schnurr M, Le TT, Mateo L, Luft T, Masterman KA, Tai TY, Chen Q, Green S, Sjölander A, Pearse MJ, Lemonnier FA, Chen W, Cebon J, Suhrbier A. Maraskovsky E, et al. Among authors: cebon j. Clin Cancer Res. 2004 Apr 15;10(8):2879-90. doi: 10.1158/1078-0432.ccr-03-0245. Clin Cancer Res. 2004. PMID: 15102697

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

304 results

Search Page